Status:
COMPLETED
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
Lead Sponsor:
Conatus Pharmaceuticals Inc.
Collaborating Sponsors:
Idun Pharmaceuticals
Conditions:
Liver Transplantation
Hepatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate ...
Detailed Description
The occurrence of apoptosis in liver ischemia/reperfusion injury has been well characterized in animal models. In this context apoptosis has specifically been observed in sinusoidal endothelial cells ...
Eligibility Criteria
Inclusion
- Minimum adult age
Exclusion
- Fulminant hepatic failure (UNOS Status I patients)
- Previous liver transplantation
- Patients undergoing split liver grafts
- Extrahepatic malignancy
- If female, pregnant or lactating
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00080236
Start Date
November 1 2003
End Date
January 1 2006
Last Update
August 10 2012
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Scottsdale
Phoenix, Arizona, United States, 85054
2
University of California Los Angeles
Los Angeles, California, United States, 90095
3
University of California San Francisco
San Francisco, California, United States, 94143
4
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202